Following the release of promising clinical trial data, the shares of Palisade Bio, Inc. (NASDAQ: PALI) are experiencing a notable surge on the US stock charts. As of the last check during current session, PALI stock recorded a remarkable uptick of 105.77%, reaching $8.56.
Palisade Bio (PALI) has disclosed today the successful culmination of its scrutiny evaluating ex-vivo bioactivation of PALI-2108. PALI-2108 is an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in the developmental phase, targeting patients afflicted by UC.
The findings have unveiled that PALI-2108 showcases proficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples, sourced from both healthy volunteers and UC patients. The enzymatic activity in stool samples was gauged through LC-MS analysis, with all samples meeting the target conversion rate within a 24-hour timeframe.
The evaluation has revealed that PALI-2108 was transmutated into its active PDE4 inhibitor form at an average rate of 90.1%, with conversion exhibiting a consistent upward trend over time. This study was conducted in collaboration with Altasciences, headquartered in Montreal, QC. These results fortify Palisade Bio’s confidence in PALI-2108 as a precisely targeted therapy for moderate-to-severe UC.
The successful bioactivation of PALI-2108 into its active PDE4 inhibitor form, maintaining consistently high conversion rates over a 24-hour duration in stool samples, accentuates its potential as an innovative therapeutic intervention for managing UC. Palisade Bio recently participated in IBD Innovate: Product Development for Crohn’s & Colitis, held on April 9-10, 2024, in Cambridge, MA.
As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research collaborator, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio, delivered an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” elucidating on the development of PALI-2108, its distinctive features, competitive positioning, and the clinical trajectory toward late-stage development.
As previously disclosed, the progression of PALI-2108 is backed by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.
